204 related articles for article (PubMed ID: 37356988)
21. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
Mato AR; Thompson M; Allan JN; Brander DM; Pagel JM; Ujjani CS; Hill BT; Lamanna N; Lansigan F; Jacobs R; Shadman M; Skarbnik AP; Pu JJ; Barr PM; Sehgal AR; Cheson BD; Zent CS; Tuncer HH; Schuster SJ; Pickens PV; Shah NN; Goy A; Winter AM; Garcia C; Kennard K; Isaac K; Dorsey C; Gashonia LM; Singavi AK; Roeker LE; Zelenetz A; Williams A; Howlett C; Weissbrot H; Ali N; Khajavian S; Sitlinger A; Tranchito E; Rhodes J; Felsenfeld J; Bailey N; Patel B; Burns TF; Yacur M; Malhotra M; Svoboda J; Furman RR; Nabhan C
Haematologica; 2018 Sep; 103(9):1511-1517. PubMed ID: 29880613
[TBL] [Abstract][Full Text] [Related]
22. The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia.
Eyre TA; Roeker LE; Fox CP; Gohill SH; Walewska R; Walter HS; Forconi F; Broom A; Arumainathan A; Brander DM; Allan JN; Schuster SJ; Hill BT; Lansigan F; Cheson BD; Lamanna N; Coombs CC; Barr PM; Skarbnik AP; Shadman M; Ujjani CS; Pearson L; Pagel JM; Jacobs R; Mato AR
Br J Haematol; 2020 Mar; 188(6):918-923. PubMed ID: 31682002
[TBL] [Abstract][Full Text] [Related]
23. Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor.
Wierda WG; Byrd JC; Davids MS; Furman RR; Cheson BD; Barr PM; Eradat H; Heffner L; Zhou L; Verdugo M; Potluri J; Choi M
Br J Haematol; 2019 Jun; 185(5):961-966. PubMed ID: 30478940
[No Abstract] [Full Text] [Related]
24. Venetoclax: A novel B-cell lymphoma-2 inhibitor for chronic lymphocytic leukemia and other hematologic malignancies.
Olin JL; Griffiths CL; Smith MB
J Oncol Pharm Pract; 2018 Oct; 24(7):517-524. PubMed ID: 28696175
[TBL] [Abstract][Full Text] [Related]
25. Autoimmune hemolytic anemia, adverse event to venetoclax.
Carriles C; Ordóñez-Fernández L; Arias-Martínez A; Menárguez-Blanc R; Rosado-María MC
Farm Hosp; 2019 Sep; 43(5):166-167. PubMed ID: 31469630
[No Abstract] [Full Text] [Related]
26. The combination of venetoclax and rituximab for the treatment of patients with recurrent chronic lymphocytic leukemia.
Vitale C; Ferrajoli A
Expert Rev Hematol; 2020 Aug; 13(8):885-894. PubMed ID: 32700593
[TBL] [Abstract][Full Text] [Related]
27. Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia.
Scott LJ
Target Oncol; 2019 Oct; 14(5):493-504. PubMed ID: 31542870
[TBL] [Abstract][Full Text] [Related]
28. Venetoclax (Venclexta) for chronic lymphocytic leukemia.
Med Lett Drugs Ther; 2016 Aug; 58(1500):101-2. PubMed ID: 27466751
[No Abstract] [Full Text] [Related]
29. Venetoclax: Management and Care for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
.
Brumbaugh Paradis H; Alter D; Llerandi D
Clin J Oncol Nurs; 2017 Oct; 21(5):604-610. PubMed ID: 28945711
[TBL] [Abstract][Full Text] [Related]
30. Persistent splenomegaly due to littoral cell angiomatosis in venetoclax-induced undetectable minimal residual disease of chronic lymphocytic leukemia.
Cellini A; Scarmozzino F; Friziero A; Trimarco V; Dei Tos AP; Trentin L; Pizzi M; Visentin A
Ann Hematol; 2023 Mar; 102(3):681-682. PubMed ID: 36542103
[No Abstract] [Full Text] [Related]
31. Venetoclax and obinutuzumab for frontline treatment of chronic lymphocytic leukemia.
Stephens DM
Blood; 2019 Nov; 134(20):1691-1696. PubMed ID: 31488409
[TBL] [Abstract][Full Text] [Related]
32. Use of venetoclax combination regimens in chronic lymphocytic leukemia.
Tam CS
Clin Adv Hematol Oncol; 2021 Aug; 19(8):504-506. PubMed ID: 34411069
[No Abstract] [Full Text] [Related]
33. Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.
Freise KJ; Jones AK; Menon RM; Verdugo ME; Humerickhouse RA; Awni WM; Salem AH
Hematol Oncol; 2017 Dec; 35(4):679-684. PubMed ID: 27982454
[TBL] [Abstract][Full Text] [Related]
34. Remission of acquired von Willebrand syndrome in a patient with chronic lymphocytic leukemia treated with venetoclax.
Innocenti I; Morelli F; Autore F; Tomasso A; Corbingi A; Bellesi S; Za T; De Stefano V; Laurenti L
Leuk Lymphoma; 2019 Dec; 60(12):3078-3080. PubMed ID: 31106622
[No Abstract] [Full Text] [Related]
35. Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy.
Popovic R; Dunbar F; Lu C; Robinson K; Quarless D; Warder SE; Mukherjee N; Pesko J; Souers AJ; Waring JF; Davids MS; Tausch E; Stilgenbauer S; Ross JA; Leverson JD; Kim SY; Chyla BJ
Am J Hematol; 2022 Feb; 97(2):E47-E51. PubMed ID: 34779028
[No Abstract] [Full Text] [Related]
36. [Resistance mechanisms and treatment strategies of Venetoclax in chronic lymphocytic leukemia].
Zou HS; Yi SH; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2020 Sep; 41(9):783-787. PubMed ID: 33113617
[No Abstract] [Full Text] [Related]
37. An update of venetoclax and obinutuzumab in chronic lymphocytic leukemia.
Salvaris R; Opat S
Future Oncol; 2021 Feb; 17(4):371-387. PubMed ID: 33064021
[TBL] [Abstract][Full Text] [Related]
38. Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia.
Hengeveld PJ; Schilperoord-Vermeulen J; van der Klift MY; Dubois JMN; Kolijn PM; Kavelaars FG; Rijken M; Dobber JA; Nasserinejad K; Kersting S; Westerweel PE; Kater AP; Langerak AW; Levin MD
Blood Cancer J; 2023 Jul; 13(1):102. PubMed ID: 37400508
[No Abstract] [Full Text] [Related]
39. Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement.
Reda G; Cassin R; Dovrtelova G; Matteo C; Giannotta J; D'Incalci M; Cortelezzi A; Zucchetti M
Haematologica; 2019 May; 104(5):e222-e223. PubMed ID: 30765472
[No Abstract] [Full Text] [Related]
40. Venetoclax plus rituximab for chronic lymphocytic leukaemia.
Stirrups R
Lancet Oncol; 2018 May; 19(5):e233. PubMed ID: 29606585
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
